Background Curcumin is the main active ingredient of the spice turmeric, investigated
extensively for putative anticancer properties. Objectives This phase IIa open-labelled …

Background The need for low toxicity adjuncts to standard care chemotherapy in inoperable
colorectal cancer, with potential to improve outcomes and decrease the side-effect burden …

Despite the use of surgical resection and aggressive chemotherapy, nearly 50% of patients
with colorectal carcinoma develop recurrent disease, highlighting the need for improved …

Colorectal cancer (CRC) is the second cause of cancer death worldwide. The metastatic
disease is mainly treated with aggressive therapies consisting on combinations of cytotoxic …

Curcumin, the main constituent of turmeric, is suspected to possess cancer chemopreventive
properties. Pharmacokinetic and pharmacodynamic parameters have been reported, but few …

Background Curcumin is the major yellow pigment extracted from turmeric, a commonly-
used spice in India and Southeast Asia that has broad anticarcinogenic and cancer …

Curcumin (diferuloylmethane), which has no discernible toxicity, inhibits initiation, promotion
and progression of carcinogenesis. 5-Fluorouracil (5-FU) or 5-FU plus oxaliplatin (FOLFOX) …

In vitro and pre-clinical studies have suggested that addition of the diet-derived agent
curcumin may provide a suitable adjunct to enhance efficacy of chemotherapy in models of …

Curcumin is a polyphenol derived from Curcuma longa. Over the last few years, a number of
studies have provided evidence of its main pharmacological properties including …

Introduction: Curcumin has been extensively studied for its anti-cancer properties. While a
diverse array of in vitro and preclinical research support the prospect of curcumin use as an …